Creating improved gene therapy vectors for muscular dystrophies
Official title: Development of optimized AAVrh74 vectors for gene therapy of muscular dystrophies
Funded at University of Florida · NIH-10768732 · Data updated 2026-11-12
This study is working on improving a type of virus used in gene therapy to help treat Duchenne muscular dystrophy (DMD) by making it safer and more effective, so that patients can benefit from better treatments with fewer side effects.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Florida NIH-funded |
| Lab location | 1 site (Gainesville, United States) |
| Project start | January 25, 2023 |
| Project end | December 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $163,754 |
| NIH project number | 5R21AR081018-02 |
| Project ID | NIH-10768732 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are children aged 0-21 diagnosed with Duchenne muscular dystrophy or related muscular dystrophies.
✕Less likely to help
Patients with muscular dystrophies other than Duchenne or those outside the age range of 0-21 may not benefit from this research.
What this research studies
This research focuses on developing advanced adeno-associated virus (AAV) vectors to enhance gene therapy for Duchenne muscular dystrophy (DMD). The team aims to modify the AAV capsid protein and genome to create more effective and less immunogenic vectors, which could deliver therapeutic genes more efficiently. By combining these modifications, the researchers hope to significantly improve the efficacy of gene therapy while minimizing adverse effects. This work is particularly relevant as current therapies have faced challenges, including serious side effects in clinical trials.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective gene therapies for children with muscular dystrophies, potentially improving their quality of life.
How similar studies have gone: Previous research has shown promise with AAV vectors in gene therapy, but this approach aims to address limitations seen in earlier trials, making it a novel and potentially groundbreaking effort.
Where this research is happening
-
University of Florida
Gainesville, United States Active
Researchers
- Principal investigator: Srivastava, Arun — University of Florida
- Study coordinator: Srivastava, Arun
Related research
Other NIH-funded projects on the same topics.
-
Noninvasive breathing imaging to guide care for people with muscular dystrophy
A noninvasive imaging tool called electrical impedance tomography (EIT) will be studied to help decide when to start noninvasive ventilation for people with muscular dystrophy.
-
Bicistronic gene therapy for limb girdle muscular dystrophy type R9
A patient-facing overview of a first-in-class gene therapy approach using two genes delivered by AAV to help people with LGMDR9.
-
Understanding why scarring happens in muscular dystrophy muscles
Researchers are studying why scar tissue forms in muscles affected by muscular dystrophy and how to slow or reverse it in patients.
-
Addressing Shortcomings of AAV Gene Therapies for Muscular Dystrophy
A national research center is working to improve AAV-based gene therapies for Duchenne and related muscular dystrophies so that patients may get safer, more effective treatments.
-
Two-gene AAV therapy for Limb-Girdle Muscular Dystrophy R9
Developing a two-gene AAV gene therapy to replace the faulty gene and rebuild muscle for people with LGMDR9 (Limb Girdle Muscular Dystrophy Type R9).
-
Improving Gene Therapies for Muscular Dystrophies
This center is working to improve gene therapies for Duchenne and Limb Girdle Muscular Dystrophy, aiming to make them safer and more effective for patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.